Jonathan Zalevsky - Dec 13, 2023 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Chief R&D Officer
Signature
Mark A. Wilson, Attorney-in-Fact
Stock symbol
NKTR
Transactions as of
Dec 13, 2023
Transactions value $
$0
Form type
4
Date filed
12/15/2023, 06:07 PM
Previous filing
Nov 20, 2023
Next filing
Feb 22, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +250K $0.00 250K Dec 13, 2023 Common Stock 250K $0.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option vests over three years from the date of grant, (December 13, 2023) in equal monthly installments based on continued service.